Synchron Pauses Brain Implant Trial Enrollment
The company says a faulty lead cable in its second-generation Stentrode system prompted the voluntary pause at trial sites.
Updated on Nov. 12, 2026 in Stroke

Live Poll
Would you trust a brain implant company to fix its device problems before resuming patient enrollment?
Synchron has voluntarily paused enrollment in its brain implant trials across the United States, Australia and Canada over a performance problem with the lead cable that carries signals from the Stentrode implant. The company says the issue does not involve the Stentrode itself and that no device-related safety issues have been identified.
Why it matters
The pause delays progress for a device designed to let people with paralysis control digital devices using their thoughts, and it comes as the company restructures its workforce. Because the decision was Synchron's own rather than an FDA order, the timeline for resuming trials depends on the company's hardware upgrade.
The first-generation COMMAND study enrolled six patients, all of whom met the 12-month primary endpoint of no device-related serious adverse events. Two of five US trial sites contacted confirmed they have stopped enrolling, and when enrollment resumes remains unannounced.
The players
Synchron
Synchron is a brain-computer interface company that develops the Stentrode, a catheter-delivered implant designed to let people with paralysis control digital devices.
The details
The Stentrode is implanted through the blood vessels without open-brain surgery, and some participants already have the second-generation device implanted. Synchron is upgrading the whole Stentrode system before enrollment restarts, and the pause covers its trial sites in the US, Australia and Canada.
Timeline
Earlier this spring: Synchron launched its multisite US trial with sites in Australia and Canada.
November 2025: Synchron announced a $200 million Series D round and a plan for a San Diego hub.
November 12, 2026: The enrollment pause and restructuring were reported.
Big Picture
The pause follows the COMMAND study, in which all six first-generation Stentrode patients met the 12-month safety endpoint, and it tests whether the endovascular approach can scale to the second-generation system. Synchron's hardware fix will determine whether that record carries into the next generation of its brain implant.
For people with paralysis who hoped to join a Stentrode trial, enrollment at the paused sites is not currently open, and the timing of any restart depends on Synchron's hardware upgrade. Trial participation decisions should be made with the trial sites and treating clinicians, who can confirm current enrollment status.
The takeaway
Brain implant development depends on hardware reliability as much as on early safety results, and a component fault can stall a program even when patients have fared well. Watch for Synchron's announcement of when enrollment resumes.
Further reading
For more on the treatments and research shaping stroke and neurological care, explore our Stroke coverage.
Live Poll
Would you trust a brain implant company to fix its device problems before resuming patient enrollment?



